Oncotype DX Colon Cancer Treatment Decisions

During the colon cancer journey, patients have the opportunity to undergo a genomic test called the Oncotype DX Test, which can help them make decisions about the best treatment for their specific cancer. Dr. Kozloff explains how the genomic test works and how it can aid a patient and doctor in choosing treatment options for colon cancer.

 

Mark F. Kozloff, MD: Oncotype DX may help both physicians and the patients together make treatment decisions in stage 2 as well as in stage 3 colon cancer, but we know is that there is in stage 2 patients, the majority of the patients are cured, but a percentage of the patients the cancer will come back. In stage 3, the cancer is more likely to come back, but it does not come back in everyone and we have a rough estimate of what the percentage is in which patients may have their cancers come back or metastasized or spared to some other part of the body. Oncotype DX actually looks at genes or what we called DNA or the very building blocks of the cancer. So it’s looking at not the genes of the person, but looking at the genes of the cancer that can tell us how malignant the cancer is and it can also better tell us what are the chances of the cancer coming back. We call that prognosticate or give a prognosis and by knowing the chances of the cancer coming back more exactly, it may help a person decide how either aggressive to be with further treatment or how nonaggressive to be with further treatment. If the Oncotype DX shows that the genes show that it is not that malignant in a person who has a very high chance of the cancer not coming back or a high chance of being cured, further treatments may not be necessary or may be less likely to be helpful and if a person has a higher chances of the cancer coming back, Oncotype DX can tell us that and that may help some patients as well as physicians to make a decision on either chemotherapy and the need for chemotherapy and how helpful it may be. So its looking at the genes to tell how malignant that the cancer is that can give us a prognosis, the likelihood of the person doing well that can then help decide a further treatment should or should not be given.
Mark F. Kozloff, MD, has more than 30 years of experience treating many types of adult cancers. He works on a multidisciplinary team of experts in the Center for Gastrointestinal Oncology where he specializes in the treatment of colorectal malignancies.

****

This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.


This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

© 2020 Cancer Answers LLC